ARPA-H pours millions into healthspan-focused human trials
ARPA-H announced up to $144 million through its PROSPR program to fund seven teams running human healthspan trials and developing early, actionable biomarkers. Awards include up to $30.8M to Cambrian BioPharma for an oral rapamycin analog and up to $22M to Linnaeus Therapeutics for a GPER-targeting drug (LNS8801).
Why it mattersARPA-H's $144M PROSPR funds biomarker-driven healthspan trials, enabling faster human proof-of-concept data to guide R&D prioritization.
Entities Mentioned
ARPA-H